Hyperkalemia is a condition that is a consequence of higher than normal levels of a substance called potassium in the blood.
At present, the treatment of Hyperkalemia is based on physical examinations, blood tests, urinalysis, electrocardiogram tests, and other such tests conducted for proper knowledge of the cause of the condition and patient’s state. However, the treatment should also focus on the efficacy and ability of the treatment by which they lower down the serum potassium levels along with a watchful eye on their side effects. The new drugs for Hyperkalemia need to be tailored as per the individuals for the best outcomes.
At present, the Hyperkalemia treatment market lacks effective therapies, standard treatment protocols, guidelines, and above all, a high cost of approved therapies adds to the burden.
To bridge the gaps in the treatment, several companies including Zeria Pharmaceutical, Vifor Pharma, and Ardelyx are proactively working to develop a standard treatment option for Hyperkalemia. No doubt that recent years have witnessed drugs walking the carpets in the Hyperkalemia treatment market with novel MoA; however, there still remains a lot to traverse.
For more detailed information, visit: Hyperkalemia Therapeutics Market